Life expectancy after a congestive heart failure diagnosis varies widely, from a few years to well over a decade, depending on the type of heart failure, how advanced it is at diagnosis, and what other health conditions are present. Older data from the Framingham Heart Study found that only 25% of men and 38% of women survived five years after diagnosis. But treatments have improved substantially since then, and many people diagnosed today live significantly longer.
What the Survival Numbers Look Like
The most useful way to understand heart failure survival is by looking at it in stages. A large study published in the Journal of the American Heart Association broke down mortality over 10 years based on how well the heart pumps, measured by ejection fraction. Ejection fraction is the percentage of blood your heart pushes out with each beat. A normal heart ejects about 50% to 70% of its blood volume. In heart failure, that number can drop significantly, or the heart can become too stiff to fill properly even when its pumping percentage looks normal.
For people whose hearts pump weakly (reduced ejection fraction), one-year mortality was about 11%, five-year mortality was 31%, and 10-year mortality was 39%. For those with a preserved ejection fraction, where the heart pumps adequately but doesn’t relax well, outcomes were notably better: 5% died within a year, 17% within five years, and 22% within 10 years. A middle category, with mildly reduced pumping, fell in between at 8%, 20%, and 25% at those same intervals.
These numbers mean that the majority of people with heart failure are alive five years after diagnosis, and a substantial portion live a decade or longer, particularly those whose hearts still pump reasonably well.
How Severity at Diagnosis Shapes Outlook
Doctors classify heart failure into four functional classes based on how much physical activity you can handle. Class I means you have no symptoms during ordinary activity. Class IV means you’re short of breath even at rest. Most people fall somewhere in the middle at the time of diagnosis.
In clinical trials tracking patients over roughly 20 months, mortality for people in class II (mild symptoms with moderate exertion) ranged from 7% to 15%. For class III (symptoms with minimal activity), it ranged from 12% to 26%. The variation reflects differences across study populations, but the pattern is consistent: more severe symptoms at diagnosis correspond to shorter survival. People diagnosed early, while still in class I or II, have meaningfully more time ahead of them than those diagnosed after the disease has progressed.
Why the Type of Heart Failure Matters
Heart failure with reduced ejection fraction and heart failure with preserved ejection fraction are not just different labels. They carry different risks and, importantly, different causes of death. When the heart pumps weakly, cardiac-related death dominates. At 10 years, 25% of people with reduced ejection fraction had died from cardiac causes specifically, compared to just 8% of those with preserved ejection fraction.
People with preserved ejection fraction face a different pattern. The majority of their deaths, about 62%, come from noncardiac causes: cancer, infections, kidney disease, and other conditions of aging. In fact, their rate of noncardiac death exceeded cardiac death from the very start of follow-up. This distinction matters because it means that for many people with preserved ejection fraction, managing overall health is just as important as managing the heart itself.
How Other Health Conditions Affect Survival
Heart failure rarely exists in isolation. Most people diagnosed with it also have other chronic conditions, and these can substantially shorten life expectancy. Chronic kidney disease is one of the strongest predictors. Patients with moderate kidney impairment are about 22% more likely to die over a three-year period than matched patients without kidney disease. As kidney function declines further, the risk climbs steeply. People with severe kidney disease (the stage just before dialysis becomes necessary) face roughly double the risk of death, and those with the most advanced kidney failure face a sevenfold increase.
Diabetes, high blood pressure, obesity, and atrial fibrillation all add their own layers of risk. The more of these conditions you carry alongside heart failure, the more compressed the survival timeline tends to be. Conversely, people diagnosed with heart failure who have few comorbidities and catch it early often do far better than the averages suggest.
Modern Treatments Are Extending Lives
The survival statistics most commonly cited in older studies paint a grimmer picture than what’s possible today. A class of medications originally developed for diabetes, called SGLT2 inhibitors, has proven to reduce all-cause mortality in heart failure patients with reduced ejection fraction by about 25%. Combined with other cornerstone therapies that reduce strain on the heart, modern treatment regimens give patients a significantly better outlook than the numbers from even 10 or 15 years ago would suggest.
Staying on a full medication regimen matters enormously. Studies consistently show that the survival benefit comes from using multiple therapies together, each targeting a different mechanism of heart failure. Missing one component of treatment can meaningfully reduce the overall benefit.
Options for Advanced Heart Failure
For people whose heart failure progresses despite optimal medical therapy, more intensive interventions exist. A left ventricular assist device (LVAD), a mechanical pump surgically implanted to help the heart circulate blood, offers meaningful survival. In registry data, one-year survival with an LVAD was 84%, two-year survival was 79%, and survival through seven years was still above 50%.
Heart transplantation remains the most effective option for end-stage heart failure. Adults who receive a heart transplant have a median survival of 12.5 years, meaning half live longer than that. Transplant availability is limited by donor organ supply, so LVADs often serve as a bridge while patients wait, or as a long-term solution for those who aren’t transplant candidates.
What Influences Your Individual Outlook
Population-level statistics are useful for understanding the general trajectory of heart failure, but individual outcomes vary enormously. The factors that matter most include how early the condition is caught, your ejection fraction, how well you respond to medications, whether you have coexisting conditions like kidney disease or diabetes, and your age at diagnosis. A 55-year-old diagnosed with mild heart failure and no other major health problems has a very different trajectory than a 78-year-old diagnosed with advanced symptoms and kidney disease.
Lifestyle factors play a measurable role too. Reducing sodium intake, staying physically active within your limits, maintaining a healthy weight, and monitoring daily fluid balance all contribute to fewer hospitalizations and slower disease progression. Heart failure hospitalizations are themselves a marker of worsening disease, and each one is associated with a stepwise decline in long-term survival. Avoiding those hospitalizations through consistent self-management and medication adherence is one of the most impactful things you can do to extend your life with this condition.